Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

Fig. 4

In vivo reconstitution of healthy human hematopoietic compartments in peripheral blood. Comparable profile between TEG001 and TEG-LM1 mock group of reconstituted healthy human hematopoietic cellular subsets, including CD14+ monocytes (a) B cells (b), T cells (c), and CD34+ progenitor cells (d) as measured by flow cytometry. Data represent mean ± SD of all mice per group (n = 10)

Back to article page